GLC-001
Glaucoma
A small-molecule program aimed at restoring aqueous outflow through the trabecular meshwork to lower intraocular pressure in glaucoma.
- Therapeutic area
- Ophthalmology
- Target
- Undisclosed (trabecular meshwork outflow)
- Modality
- Small Molecule
- Ownership
- Fully Owned
Why this program
The pressure problem
Glaucoma is a leading cause of irreversible blindness. In its most common forms, fluid drains too slowly through the eye’s trabecular meshwork, raising intraocular pressure and progressively damaging the optic nerve. Lowering that pressure is the only intervention proven to slow the disease.
Targeting outflow directly
Rather than reducing fluid production, this program addresses the source of resistance in the trabecular-meshwork outflow pathway, with the goal of durable pressure reduction.
How we got here
AI-guided discovery
Omic’s AI scientists explored candidate chemistries against the outflow mechanism and ranked molecules on predicted efficacy and tolerability, with each ranking traceable to the evidence behind it.
Where it stands
The program is in lead optimization. The specific molecular target remains undisclosed.